{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:49:57Z","timestamp":1769845797274,"version":"3.49.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>ERG gene fusions are present in up to 60% of localized prostate cancer and up to 45% of metastatic prostate cancer. Fluorescence in situ hybridization (FISH) assays can detect the vast majority of ERG gene fusions and help confirm prostatic origin. We reviewed clinical ERG FISH assays performed at our tertiary institution by our in-house consult services between 2016 and 2024 where prostatic adenocarcinoma was in the differential diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We summarized clinical information, immunohistochemistry results (including ERG), and ERG FISH status in a cohort of 15 consecutive clinical ERG FISH assays performed for 14 patients in whom a diagnosis of prostatic adenocarcinoma was considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ERG FISH testing was positive in 7 of 15 (46.7%) cases, indeterminate in 1 of 15 (6.7%) cases, and negative in 7 of 15 (46.7%) cases. In 6 of 7 (85.7%) positive cases, the ERG FISH-positive result supported prostatic origin in metastatic (n\u2009=\u20094) or undifferentiated (n\u2009=\u20092) disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Use of clinical ERG FISH assays may help confirm prostatic origin in the setting of localized or metastatic carcinoma showing poor differentiation or transdifferentiation and thus help determine the correct diagnosis and direct appropriate clinical management for such patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqaf128","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T12:48:35Z","timestamp":1761482915000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical\n                    <i>ERG<\/i>\n                    break-apart fluorescence in situ hybridization assay: practical utility and lessons from an 8-year tertiary institution experience"],"prefix":"10.1093","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0509-9674","authenticated-orcid":false,"given":"Robert M","family":"Humble","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radha","family":"Paturu","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School , Ann Arbor, MI,","place":["United States"]},{"name":"Center for Translational Pathology , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiko","family":"Iwata-Otsubo","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saravana M","family":"Dhanasekaran","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School , Ann Arbor, MI,","place":["United States"]},{"name":"Center for Translational Pathology , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah A","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan L","family":"Betz","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette S","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L","family":"Myers","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arul M","family":"Chinnaiyan","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School , Ann Arbor, MI,","place":["United States"]},{"name":"Center for Translational Pathology , Ann Arbor, MI,","place":["United States"]},{"name":"Rogel Cancer Center, Michigan Medicine , Ann Arbor, MI,","place":["United States"]},{"name":"Department of Urology, University of Michigan Medical School , Ann Arbor, MI,","place":["United States"]},{"name":"Howard Hughes Medical Institute , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Mehra","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School , Ann Arbor, MI,","place":["United States"]},{"name":"Center for Translational Pathology , Ann Arbor, MI,","place":["United States"]},{"name":"Rogel Cancer Center, Michigan Medicine , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"2026012923370951700_aqaf128-B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/PPO.0000000000000017","article-title":"Current and proposed molecular diagnostics in a genitourinary service line laboratory at a tertiary clinical institution","volume":"20","author":"Udager","year":"2014","journal-title":"Cancer J"},{"key":"2026012923370951700_aqaf128-B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026012923370951700_aqaf128-B3","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/modpathol.3800769","article-title":"Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer","volume":"20","author":"Mehra","year":"2007","journal-title":"Mod Pathol"},{"key":"2026012923370951700_aqaf128-B4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"2026012923370951700_aqaf128-B5","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/modpathol.2009.79","article-title":"Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma","volume":"22","author":"Han","year":"2009","journal-title":"Mod Pathol"},{"key":"2026012923370951700_aqaf128-B6","doi-asserted-by":"publisher","first-page":"7991","DOI":"10.1158\/0008-5472.CAN-07-2043","article-title":"Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases","volume":"67","author":"Mehra","year":"2007","journal-title":"Cancer Res"},{"key":"2026012923370951700_aqaf128-B7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/jcp-2022-208350","article-title":"Gene of the month: ERG","volume":"75","author":"Mullen","year":"2022","journal-title":"J Clin Pathol"},{"key":"2026012923370951700_aqaf128-B8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1593\/neo.07822","article-title":"Role of the TMPRSS2-ERG gene fusion in prostate cancer","volume":"10","author":"Tomlins","year":"2008","journal-title":"Neoplasia"},{"key":"2026012923370951700_aqaf128-B9","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1158\/0008-5472.CAN-07-6154","article-title":"Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer","volume":"68","author":"Mehra","year":"2008","journal-title":"Cancer Res"},{"key":"2026012923370951700_aqaf128-B10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1158\/0008-5472.CAN-07-3224","article-title":"A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer","volume":"68","author":"Laxman","year":"2008","journal-title":"Cancer Res"},{"key":"2026012923370951700_aqaf128-B11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1593\/neo.06625","article-title":"Noninvasive detection of TMPRSS2: ERG fusion transcripts in the urine of men with prostate cancer","volume":"8","author":"Laxman","year":"2006","journal-title":"Neoplasia"},{"key":"2026012923370951700_aqaf128-B12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41391-022-00633-3","article-title":"MyProstateScore in men considering repeat biopsy: validation of a simple testing approach","volume":"26","author":"Tosoian","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026012923370951700_aqaf128-B13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.urology.2021.11.033","article-title":"Urinary MyProstateScore (MPS) to rule out clinically-significant cancer in men with equivocal (PI-RADS 3) multiparametric MRI: addressing an unmet clinical need","volume":"164","author":"Tosoian","year":"2022","journal-title":"Urology"},{"key":"2026012923370951700_aqaf128-B14","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1593\/neo.10726","article-title":"Antibody-based detection of ERG rearrangement-positive prostate cancer","volume":"12","author":"Park","year":"2010","journal-title":"Neoplasia"},{"key":"2026012923370951700_aqaf128-B15","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.ccell.2024.07.009","article-title":"Development of peptidomimetic inhibitors of the ERG gene fusion product in prostate cancer","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"2026012923370951700_aqaf128-B16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s12032-018-1212-6","article-title":"Association of ERG\/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer","volume":"35","author":"Mehra","year":"2018","journal-title":"Med Oncol"},{"key":"2026012923370951700_aqaf128-B17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1136\/jclinpath-2013-201586","article-title":"Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma","volume":"66","author":"Downes","year":"2013","journal-title":"J Clin Pathol"},{"key":"2026012923370951700_aqaf128-B18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1309\/AJCP3K5VUFALZTKC","article-title":"ERG protein expression in human tumors detected with a rabbit monoclonal antibody","volume":"138","author":"Yaskiv","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"2026012923370951700_aqaf128-B19","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1158\/1078-0432.CCR-08-2927","article-title":"Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States","volume":"15","author":"Mosquera","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026012923370951700_aqaf128-B20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nature06024","article-title":"Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer","volume":"448","author":"Tomlins","year":"2007","journal-title":"Nature"},{"key":"2026012923370951700_aqaf128-B21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13000-021-01096-1","article-title":"Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver: a series of four cases","volume":"16","author":"Bell","year":"2021","journal-title":"Diagn Pathol"},{"key":"2026012923370951700_aqaf128-B22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/modpathol.2017.99","article-title":"Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays","volume":"31","author":"Skala","year":"2018","journal-title":"Mod Pathol"},{"key":"2026012923370951700_aqaf128-B23","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/ajcp\/aqad089","article-title":"Lessons from 801 clinical TFE3\/TFEB fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrations","volume":"160","author":"Wang","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"2026012923370951700_aqaf128-B24","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/pros.22836","article-title":"Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer","volume":"74","author":"Udager","year":"2014","journal-title":"Prostate"},{"key":"2026012923370951700_aqaf128-B25","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/modpathol.2011.7","article-title":"ERG gene rearrangements are common in prostatic small cell carcinomas","volume":"24","author":"Lotan","year":"2011","journal-title":"Mod Pathol"},{"key":"2026012923370951700_aqaf128-B26","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.humpath.2013.05.005","article-title":"Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry","volume":"44","author":"Schelling","year":"2013","journal-title":"Hum Pathol"},{"key":"2026012923370951700_aqaf128-B27","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1038\/s41379-020-0543-y","article-title":"Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer","volume":"33","author":"Chan","year":"2020","journal-title":"Mod Pathol"},{"key":"2026012923370951700_aqaf128-B28","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/his.12493","article-title":"Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin","volume":"66","author":"Rodrigues","year":"2015","journal-title":"Histopathology"},{"key":"2026012923370951700_aqaf128-B29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.humpath.2022.07.002","article-title":"De novo neuroendocrine features in prostate cancer","volume":"127","author":"Abdulfatah","year":"2022","journal-title":"Hum Pathol"},{"key":"2026012923370951700_aqaf128-B30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12032-021-01473-2","article-title":"De novo neuroendocrine transdifferentiation in primary prostate cancer\u2014a phenotype associated with advanced clinico-pathologic features and aggressive outcome","volume":"38","author":"Abdulfatah","year":"2021","journal-title":"Med Oncol"},{"key":"2026012923370951700_aqaf128-B31","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1038\/modpathol.2017.164","article-title":"Neuroendocrine tumors of the prostate","volume":"31","author":"Fine","year":"2018","journal-title":"Mod Pathol"},{"key":"2026012923370951700_aqaf128-B32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.32074\/1591-951X-19-19","article-title":"Expression of CDX2 in metastatic prostate cancer","volume":"111","author":"Guerrieri","year":"2019","journal-title":"Pathologica"},{"key":"2026012923370951700_aqaf128-B33","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.3390\/ijms23094772","article-title":"The expression of proto-oncogene ETS-Related Gene (ERG) plays a central role in the oncogenic mechanism involved in the development and progression of prostate cancer","volume":"23","author":"Khosh Kish","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026012923370951700_aqaf128-B34","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/cancers14051118","article-title":"Past, current, and future strategies to target ERG fusion-positive prostate cancer","volume":"14","author":"Lorenzin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026012923370951700_aqaf128-B35","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.cell.2009.11.030","article-title":"Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer","volume":"139","author":"Lin","year":"2009","journal-title":"Cell"},{"key":"2026012923370951700_aqaf128-B36","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1016\/j.celrep.2016.11.019","article-title":"Inflammation-induced oxidative stress mediates gene fusion formation in prostate cancer","volume":"17","author":"Mani","year":"2016","journal-title":"Cell Rep"},{"key":"2026012923370951700_aqaf128-B37","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1126\/science.1178124","article-title":"Induced chromosomal proximity and gene fusions in prostate cancer","volume":"326","author":"Mani","year":"2009","journal-title":"Science"},{"key":"2026012923370951700_aqaf128-B38","doi-asserted-by":"publisher","first-page":"E1; discussion E2","DOI":"10.1038\/nature07738","article-title":"ETS rearrangements and prostate cancer initiation","volume":"457","author":"Carver","year":"2009","journal-title":"Nature"},{"key":"2026012923370951700_aqaf128-B39","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1073\/pnas.0711711105","article-title":"A causal role for ERG in neoplastic transformation of prostate epithelium","volume":"105","author":"Klezovitch","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026012923370951700_aqaf128-B40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/ng.370","article-title":"Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate","volume":"41","author":"Carver","year":"2009","journal-title":"Nat Genet"},{"key":"2026012923370951700_aqaf128-B41","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/ng.371","article-title":"Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis","volume":"41","author":"King","year":"2009","journal-title":"Nat Genet"},{"key":"2026012923370951700_aqaf128-B42","doi-asserted-by":"publisher","first-page":"R155","DOI":"10.1530\/ERC-12-0285","article-title":"Current mouse and cell models in prostate cancer research","volume":"20","author":"Wu","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"2026012923370951700_aqaf128-B43","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/1471-2407-11-507","article-title":"TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling","volume":"11","author":"Brase","year":"2011","journal-title":"BMC Cancer"},{"key":"2026012923370951700_aqaf128-B44","doi-asserted-by":"publisher","first-page":"e21650","DOI":"10.1371\/journal.pone.0021650","article-title":"TMPRSS2\/ERG promotes epithelial to mesenchymal transition through the ZEB1\/ZEB2 axis in a prostate cancer model","volume":"6","author":"Leshem","year":"2011","journal-title":"PLoS One"},{"key":"2026012923370951700_aqaf128-B45","doi-asserted-by":"publisher","first-page":"25115","DOI":"10.18632\/oncotarget.15931","article-title":"TMPRSS2: ERG gene fusion variants induce TGF-\u03b2 signaling and epithelial to mesenchymal transition in human prostate cancer cells","volume":"8","author":"Ratz","year":"2017","journal-title":"Oncotarget"},{"key":"2026012923370951700_aqaf128-B46","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ccell.2017.02.004","article-title":"SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K\/mTOR and AR signaling","volume":"31","author":"Blattner","year":"2017","journal-title":"Cancer Cell."},{"key":"2026012923370951700_aqaf128-B47","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41467-020-20820-x","article-title":"Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer","volume":"12","author":"Bernasocchi","year":"2021","journal-title":"Nat Commun"},{"key":"2026012923370951700_aqaf128-B48","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat Genet"},{"key":"2026012923370951700_aqaf128-B49","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Cancer Genome Atlas Research Network","year":"2015","journal-title":"Cell."},{"key":"2026012923370951700_aqaf128-B50","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2026012923370951700_aqaf128-B51","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-18-0937","article-title":"SPOP-mutated\/CHD1-deleted lethal prostate cancer and abiraterone sensitivity","volume":"24","author":"Boysen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026012923370951700_aqaf128-B52","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ccell.2017.02.017","article-title":"Development of peptidomimetic inhibitors of the ERG gene fusion product in prostate cancer","volume":"31","author":"Wang","year":"2017","journal-title":"Cancer Cell"},{"key":"2026012923370951700_aqaf128-B53","doi-asserted-by":"publisher","first-page":"e2102555","DOI":"10.1002\/advs.202102555","article-title":"Destruction of DNA-binding proteins by programmable oligonucleotide PROTAC (O\u2019PROTAC): effective targeting of LEF1 and ERG","volume":"8","author":"Shao","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"2026012923370951700_aqaf128-B54","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41416-020-0951-2","article-title":"Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer","volume":"123","author":"Li","year":"2020","journal-title":"Br J Cancer"},{"key":"2026012923370951700_aqaf128-B55","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1158\/1535-7163.MCT-22-0527","article-title":"Emerging developments in ETS-positive prostate cancer therapy","volume":"22","author":"Bowling","year":"2023","journal-title":"Mol Cancer Ther"}],"container-title":["Am J Clin Pathol"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/1\/aqaf128\/65830365\/aqaf128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/1\/aqaf128\/65830365\/aqaf128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T04:37:17Z","timestamp":1769747837000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/doi\/10.1093\/ajcp\/aqaf128\/8376665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaf128","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,10]]},"article-number":"aqaf128"}}